Literature DB >> 24836705

Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation.

Nerea Fernandez-Ros1, Mercedes Iñarrairaegui, Jose A Paramo, Carmen Berasain, Matias A Avila, Ana Chopitea, Nerea Varo, Pablo Sarobe, Jose I Bilbao, Ines Dominguez, Delia D'Avola, J Ignacio Herrero, Jorge Quiroga, Bruno Sangro.   

Abstract

BACKGROUND & AIMS: Radioembolization may rarely induce liver disease resulting in a syndrome that is similar to veno-occlusive disease complicating bone marrow transplantation where inflammation, endothelial cell activation and thrombosis are likely involved. We hypothesized that similar mechanisms could be implicated in radioembolization-induced liver disease (REILD). Moreover, lobar radioembolization may induce hypertrophy of the non-treated hemiliver most probably by inducing liver regeneration.
METHODS: In patients with hepatocellular carcinoma, we prospectively studied serum levels of markers of liver regeneration, oxidative stress, pro-inflammatory pathways, endothelial activation and coagulation parameters over 2 months after radioembolization.
RESULTS: Although REILD did not occur among 14 treated patients, a decrease in effective liver blood flow was observed. Radioembolization was followed by a persistent increase in pro-inflammatory (interleukin 6 and 8) and oxidative stress (malondyaldehide) markers, an induction of endothelial injury markers (vW factor and PAI-1) and an activation of the coagulation cascade (factor VIII, PAI-1, D-Dimer) as well as a significant increase in factors related to liver regeneration (FGF-19 and HGF).
CONCLUSION: Radioembolization activates liver regeneration, produces oxidative stress, activates inflammatory cytokines and induces endothelial injury with partial activation of the coagulation cascade. These findings may have implications in the pathogenesis, prevention and therapy of REILD and in the development of new therapies to enhance hypertrophy with a surgical perspective.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  endothelial injury; inflammation; liver hypertrophy; liver regeneration; liver tumours; radioembolization-induced liver disease

Mesh:

Substances:

Year:  2014        PMID: 24836705     DOI: 10.1111/liv.12592

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  17 in total

1.  The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT.

Authors:  Manuel de la Torre-Aláez; Carlota Jordán-Iborra; Andrea Casadei-Gardini; José Ignacio Bilbao; Macarena Rodriguez-Fraile; Lidia Sancho; Delia D'Avola; José Ignacio Herrero; Mercedes Iñarrairaegui; Bruno Sangro
Journal:  Cardiovasc Intervent Radiol       Date:  2020-03-12       Impact factor: 2.740

2.  Radioembolization as an adjunct therapy to the resection of liver tumors.

Authors:  Mercedes Iñarrairaegui; Bruno Sangro
Journal:  Hepat Oncol       Date:  2015-11-06

Review 3.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 4.  [Contralateral hepatic hypertrophy following unilateral yttrium-90 radioembolization : Implications for liver surgery].

Authors:  B Garlipp; M Seidensticker; D Jechorek; H Ptok; C J Bruns; J Ricke
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

Review 5.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 6.  Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Authors:  Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg
Journal:  Radiology       Date:  2019-04-23       Impact factor: 11.105

Review 7.  The evolution of interventional oncology in the 21st century.

Authors:  Thomas Helmberger
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.039

8.  Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study.

Authors:  Michael Hardy; Isabelle Michaux; Alain Dive; Thomas Lecompte; François Mullier
Journal:  TH Open       Date:  2021-05-12

9.  Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization.

Authors:  Osman Öcal; Juozas Kupčinskas; Egidijus Morkunas; Holger Amthauer; Kerstin Schütte; Peter Malfertheiner; Heinz Josef Klümpen; Christian Sengel; Julia Benckert; Ricarda Seidensticker; Bruno Sangro; Moritz Wildgruber; Maciej Pech; Peter Bartenstein; Jens Ricke; Max Seidensticker
Journal:  EJNMMI Res       Date:  2021-06-02       Impact factor: 3.138

10.  Hepatobiliary Scintigraphy and Glass 90Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver.

Authors:  Carole Allimant; Emmanuel Deshayes; Marilyne Kafrouni; Lore Santoro; Delphine de Verbizier; Marjolaine Fourcade; Christophe Cassinotto; Margaux Hermida; Chloé Guillot; Denis Mariano-Goulart; Boris Guiu
Journal:  Diagnostics (Basel)       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.